Indaptus Therapeutics
INDP
6 hedge funds and large institutions have $11.9M invested in Indaptus Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
8% less capital invested
Capital invested by funds: $12.9M → $11.9M (-$1.01M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$149K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.64M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.37M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$549K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $4.76M | – | – | – |
|
|
MIFH
2
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| $2.91M | – | – | – |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $2.9M | -$1.37M | -110 | -33% |
|
|
OM
4
Opaleye Management
Boston,
Massachusetts
| $1.03M | -$2.64M | -212 | -73% |
|
|
5
Renaissance Technologies
New York
| $154K | +$149K | +12 | New |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $126K | +$124K | +10 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $4K | -$12.4K | -1 | Closed |
|
|
DCM
8
DAFNA Capital Management
Los Angeles,
California
| – | -$549K | -53 | Closed |
|
INDP Hedge Fund Activity: Q3 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2016, worth a combined $11.9M — down 7.8% from $12.9M a quarter earlier.
Fund positioning in INDP was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $149K. The largest seller was Opaleye Management, cutting an estimated $2.64M.
- 6 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $11.9M of Indaptus Therapeutics stock for Q3 2016, down 7.8% quarter-over-quarter.
- 2 funds opened new Indaptus Therapeutics positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Indaptus Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $149K added.
- The largest Indaptus Therapeutics seller in Q3 2016 was Opaleye Management, an estimated $2.64M sold.
Based on aggregated 13F filings for Q3 2016.